Stoke Therapeutics filings document regulatory disclosures for a Nasdaq-listed biotechnology company developing RNA medicines, including zorevunersen for Dravet syndrome. Recent 8-K reports cover quarterly financial results, clinical-program updates, capital resources, material agreements, lease obligations, board appointments, executive compensation, auditor changes, and Regulation FD disclosures.
The company’s definitive proxy materials describe annual meeting voting matters, director elections, board committee structure, governance practices, equity compensation, and related stockholder information. Filings also identify its common stock registered on the Nasdaq Global Select Market under STOK.
Stoke Therapeutics, Inc. (STOK) is named in a Rule 144 notice by former affiliate Edward Kaye for a planned sale of 1,496,042 common shares, with an aggregate market value of $38,418,358.56. The notice says the sales are to follow a cashless exercise of options under a registered plan, commencing October 21, 2026.
Stoke Therapeutics, Inc.'s General Counsel & Corp Sec, Jonathan Allan, sold 627 shares of common stock on October 2, 2026, at $26.33 per share. The sale was made under a Rule 10b5-1 trading plan adopted November 10, 2025. Allan's reported direct holdings after the transaction were 20,598 shares.
Stoke Therapeutics, Inc. Chief Medical Officer Barry Ticho sold 1,051 shares of common stock on October 1, 2026, at a reported weighted-average price of $26.1594 per share. The shares were sold in multiple transactions ranging from $25.91 to $26.51 per share under a Rule 10b5-1 trading plan adopted November 19, 2025. He directly held 19,059 shares after the sale.
Stoke Therapeutics, Inc. officer Jonathan D. Allan reported a proposed sale of 627 common shares, with an approximate sale date of October 2, 2026 and an aggregate market value of $16,308.27. The shares are listed as acquired from the issuer through restricted stock units on September 30, 2026. The notice also lists 2,861 shares sold on August 18, 2026, for $91,639.43 during the prior three months.
Stoke Therapeutics, Inc. (STOK) is the issuer whose common stock is covered by a Schedule 13G reporting beneficial ownership by several investment funds and related entities. As of the close of business on September 30, 2026, Biotechnology Value Fund, L.P. beneficially owned 1,866,761 shares, Biotechnology Value Fund II, L.P. 1,404,263 shares, and Biotechnology Value Trading Fund OS LP 261,006 shares. BVF Partners L.P., BVF Inc. and Mark N. Lampert, a director and officer of BVF Inc., each may be deemed to beneficially own 3,608,968 shares, approximately 5.6%; BVF GP Holdings LLC may be deemed to beneficially own 3,271,024 shares, approximately 5.1%. The 3,608,968-share figure includes 76,938 shares held in the Partners Managed Account. The reporting persons disclose shared voting and dispositive power and disclaim beneficial ownership of certain shares attributed to others.
Stoke Therapeutics, Inc. director Alexander Cumbo received a direct award of options covering 39,674 common shares on September 23, 2026, at an exercise price of $26.11 per share; the options expire September 22, 2036. The award vests in 1/12th installments quarterly, beginning December 23, 2026, subject to continued service through each vesting date. No Rule 10b5-1 plan is reported.
Stoke Therapeutics, Inc. (STOK) said Edward M. Kaye, M.D. intends to resign as a Class III director and Research and Development Committee member, effective September 23, 2026; the resignation was not the result of a disagreement with the company. The Board appointed Alexander (Bo) Cumbo as a Class III director effective September 23, 2026, to fill the vacancy. His term expires at the 2028 Annual Meeting, and the Board determined that he qualifies as an independent director.
Cumbo will receive an annual cash retainer of $45,000. On his appointment’s effective date, he was granted an initial stock option to purchase 39,674 shares, representing target grant-date fair value of approximately $724,000 under ASC 718. The option vests in twelve substantially equal quarterly installments on each quarterly anniversary of the grant date.
Stoke Therapeutics, Inc. (STOK) reported that its Chief Medical Officer, Barry Ticho, sold a total of 5,545 shares of common stock on September 1, 2026 in open-market transactions under a Rule 10b5-1 trading plan adopted on November 19, 2025. The sales were executed in multiple trades at weighted average prices within disclosed ranges.
Stoke Therapeutics, Inc. (STOK) reported insider equity activity by its Chief Medical Officer, Barry Ticho. On August 14, 2026, he exercised 10,000 performance stock units, receiving 10,000 shares of common stock at a price of $0.00 per share. On August 18, 2026, the company facilitated issuer-mandated sales of 4,525 and 242 common shares, respectively, to satisfy tax withholding liabilities tied to restricted stock unit vesting, at weighted average prices around $32 per share across specified price ranges.